Pharma Market Access Course

Lesson 1 • Key Stakeholders and Their Roles

Maps every actor influencing access decisions from manufacturers to payers. Builds stakeholder literacy needed for all subsequent chapters.

Lesson 2 • The Market Access Value Chain

Traces how a product moves from regulatory approval to patient prescription. Highlights decision points where access can be gained or lost.

Lesson 3 • Access Environments Across Markets

Compares single-payer, multi-payer, and hybrid healthcare systems. Prepares learners to adapt strategies to different market structures.

Lesson 1 • HTA Decision Outcomes and Appeals

Describes how HTA bodies communicate decisions and what options exist when outcomes are unfavourable. Prepares learners for strategic response planning.

Lesson 2 • International HTA Collaboration Trends

Examines cross-border HTA cooperation and joint clinical assessments. Signals how global alignment is reshaping national submission strategies.

Lesson 3 • Clinical Evidence Requirements in HTA

Explains what clinical data HTA bodies demand and how evidence quality is judged. Directly informs evidence generation planning covered later.

Lesson 4 • Economic Evidence in HTA

Covers cost-effectiveness and budget impact as core HTA economic inputs. Links economic modelling to reimbursement outcomes.

Lesson 1 • International Reference Pricing Dynamics

Explains how countries link their prices to those in other markets. Teaches learners to manage cross-market price interdependencies.

Lesson 2 • Pharmaceutical Pricing Mechanisms

Surveys the main methods used to set drug prices across healthcare systems. Establishes the pricing vocabulary used throughout the chapter.

Lesson 3 • Reimbursement Negotiation Strategies

Covers negotiation tactics, stakeholder alignment, and concession management in payer discussions. Builds practical negotiation readiness.

Lesson 4 • Managed Entry Agreements

Details financial and performance-based agreements used to manage uncertainty at launch. Links MEA design to HTA outcomes and pricing strategy.

Lesson 1 • Patient-Centered Evidence Development

Focuses on capturing outcomes that matter to patients and incorporating them into access arguments. Strengthens value dossiers with patient voice.

Lesson 2 • Real-World Evidence Strategy

Covers the design and use of real-world studies to complement trial data. Addresses payer expectations for post-launch evidence.

Lesson 3 • Evidence Communication and Dissemination

Addresses how to present evidence persuasively to HTA bodies and payers. Bridges evidence generation with submission and negotiation activities.

Lesson 4 • Integrated Evidence Planning Principles

Introduces the concept of planning evidence generation across the product lifecycle. Connects early planning to reduced access risk at launch.

Lesson 1 • Interpreting and Critiquing HEOR Models

Develops critical appraisal skills for evaluating third-party and competitor models. Enables learners to identify weaknesses and strengthen their own submissions.

Lesson 2 • Foundations of Health Economics

Establishes economic principles underlying healthcare resource allocation decisions. Provides the conceptual base for all modelling techniques in this chapter.

Lesson 3 • Budget Impact Analysis

Covers BIA methodology from population sizing to cost estimation. Addresses payer concerns about affordability alongside cost-effectiveness.

Lesson 4 • Cost-Effectiveness Modelling Techniques

Teaches construction of decision-tree and Markov models used in HTA submissions. Develops hands-on modelling competency.

Lesson 1 • Systematic Literature Review for Dossiers

Covers SLR methodology required to support clinical and economic evidence sections. Ensures submissions meet HTA evidence standards.

Lesson 2 • Submission Quality and Review Processes

Establishes quality standards and internal review workflows for dossier finalisation. Reduces submission errors and strengthens payer confidence.

Lesson 3 • Adapting Dossiers Across Markets

Addresses how a core global dossier is localised for different payer systems. Builds efficiency in multi-market submission programmes.

Lesson 4 • Value Dossier Architecture

Defines the structure, components, and logic flow of a complete value dossier. Establishes the blueprint used throughout the section.

Lesson 1 • Payer Segmentation and Targeting

Teaches how to prioritise and differentiate engagement across diverse payer types. Maximises resource efficiency in multi-payer environments.

Lesson 2 • Post-Launch Access Maintenance

Addresses sustaining and expanding access after initial listing. Covers lifecycle management from an access perspective.

Lesson 3 • Access Strategy Development

Guides learners through building a comprehensive market access strategy for a product. Integrates pricing, evidence, and engagement into a unified plan.

Lesson 4 • Early Payer Engagement Tactics

Covers pre-submission interactions designed to shape evidence requirements and expectations. Reduces late-stage surprises in HTA and negotiation.

Lesson 1 • Access Strategy for Specialty and Rare Diseases

Examines unique access challenges for high-cost, small-population therapies. Applies core frameworks to orphan and specialty drug contexts.

Lesson 2 • Access for Cell and Gene Therapies

Addresses the distinct access barriers posed by one-time, curative therapies. Covers novel payment and evidence models for transformative treatments.

Lesson 3 • Digital Health and Companion Diagnostics Access

Covers access pathways for digital therapeutics and biomarker-driven precision medicines. Extends access skills to non-traditional product types.

Lesson 4 • Leading Cross-Functional Access Teams

Builds leadership skills for directing access programmes across medical, commercial, and regulatory functions. Prepares learners for senior access roles.